Advanced therapies

Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No. 726/2004... 

A further committee. The Committee for Advance Therapies, is to be established under regulation (EC) No. 1394/2007 to deal with issues raised by emerging drug products based on gene therapy, somatic cell therapy and tissue engineering. 

Applications to the Ethics Committee should be made using the same application form as used for the Competent Authority. Most of the data submitted to the Competent Authority will also need to be included in the application to the Ethics Committee, although the IMPD is usually not required. Similar to the Competent Authority, the Ethics Committee is allowed 60 days to deliver an opinion (90 days for advanced therapy products), having given particular attention to the following ... 

Artificial enzymes for sequence-selective RNA scission are also important. If only one RNA can be selected from mar others in cells and is cleaved at the desired site, this shoirld open the way to new RNA science. Regulation of the expression of a specific gene in cells, advanced therapy, and RNA manipirlation are promising. However, none of the naturally occrrrring ri-bonucleases shows such a high sequence-selectivity. The so-called ribozymes are well suited for these purposes (Cech et al., 1981). However, these semi-artificial enzymes, based on RNA framework, do not necessarily fulfill all the requirements for versatile applications. The following factors sometimes impose limitations ... 

Dohar J (2004) Eardrops for Otorrhoea. In Alper CM, Bluestone C, Dohar JE, Mandel EM, Casselbrant ML (eds) Advanced therapy of otitis media. BC Decker Publications, Hamilton, pp 246-253... 

II. Extemporaneous preparations involving specific risks, such as complex aseptic handling and preparation with hazardous substances. Involved in this category is aseptic handling with most antineoplastics, medication cartridges, radiopharmaceuticals, biological or advanced therapy medicinal products (ATMP s). 

Volume 2 - Notice to applicants and regulatory guidelines for medicinal products for human use and specific rules for medicinal products for paediatric use, orphan, herbal medicinal products and advanced therapies (mentioned in Sect. 35.4.3)... 

Regulatory guidelines instruct that implant leachates should not produce adverse local, systemic, tumorigenic, reproductive, or developmental effects to be approved. Evaluations of biocompatibility, which are described in these standards, are all part of the overall safety and efficacy assessment of medical devices and advanced therapy medical products, for example, scaffolds for tissue engineering, tissue adhesives, hip replacements, and surgical meshes for tissue support. 

The advent of H. pylori eradication and appropriate acid-suppressive therapy in recent times has considerably narrowed the gap in therapeutic outcome between gastric and duodenal ulcers. The recognition that two of the major factors in defining gastric ulcer, namely H. pylori and NSAIDs, can be therapeutically addressed is mostly responsible for this advance. Therapy, therefore, for gastric ulcers has exhibited a remarkable transition, as PPI therapy combined with H. pylori eradication produced healing and recurrence... 

Cardiovascular diseases (CVD) are a leading cause of death worldwide, as treatments for CVD are stiff limited in the category of detection and advanced therapies (Mozaffarian et al, 2015). In this context, cardiovascular regenerative medicine wisely involves and integrates the use of cells, biomaterials, scaffolds, and bioreactors toward establishing environments that mimic the natural environment to promote cardiac regeneration (Freytes et al., 2014). 

SKE Advanced Therapies Italy http //w w w. ske. it/ MM, CS Lab scale electrospinning machines, cell scaffold Needle Uhknown/trade secret Own design... 

---